Skip to main content

Table 1 Principal mixed cryoglobulinemia manifestations (clinical and biohumoral) diagnosed before treatment with rituximab and 3 months after therapy

From: Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment

MC manifestations Pre-treatment 3 months
(%) (%)
Clinical   
Purpura 11 (78.56) 1 (7.1)
Arthralgias 13 (92.96) 4 (28.57)
Neuropathic symptoms 7 (50) 3 (21.43)
Renal involvment 2 (14.28) 1 (7.1)
Skin ulcers 1 (7.1) 0
Sicca syndrome 7 (50) 5 (37.71)
Biohumoral   
Cryocrit 3.36 (1–12) 1.46 (0–6)
Rheumatoid factor 12 (85.71) 10 (71.43)
Reduced C4 9 (64.3) 5 (37.71)